Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.
Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.
Celgene Corporation announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod – an investigational oral, selective S1P 1 and 5 receptor modulator – in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) β-1a (Avonex).
The U.S. FDA granted final approval to Aurobindo Pharma Limited’s generic treatment for multiple sclerosis.
A review about two promising applications of digital data to improve patient marketing, plus a third “low-hanging fruit” tactic most brands should explore.
New research published by the CVS Health Research Institute showed a significant improvement in adherence to specialty medications for patients enrolled in a pilot study evaluating Specialty Connect, CVS Health’s […]
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials – In the extension of two Phase […]
LONDON— GlaxoSmithKline GSK -3.47 % PLC is selling its remaining rights to a drug for use in treating autoimmune diseases, including multiple sclerosis, to Novartis AG NVS -3.07 % for […]
Not your father’s launches The leading members of the pharmaceutical industry’s new compound class of 2013 have set a new standard for launch success. Remember when a drug that […]
Last year, LSD took a tentative, presumably groovy step back into the medical limelight when it was the featured performer in a controlled human trial for the first time in […]
